Next Article in Journal / Special Issue
Dual Targeting of Tumor Cells with Bispecific Single-Chain Fv-Immunoliposomes
Previous Article in Journal
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Previous Article in Special Issue
A Cassette Vector System for the Rapid Cloning and Production of Bispecific Tetravalent Antibodies
Article Menu

Export Article

Open AccessReview
Antibodies 2012, 1(2), 172-198; doi:10.3390/antib1020172

Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

1
Institute of Immunology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany
2
The DFG research Center and Cluster of Excellence for Regenerative Therapies Dresden, Germany
Present address: Translational Immunology Unit, German Cancer Research Center, NCT Building, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.
*
Author to whom correspondence should be addressed.
Received: 24 May 2012 / Revised: 27 June 2012 / Accepted: 10 July 2012 / Published: 18 July 2012
(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)
View Full-Text   |   Download PDF [623 KB, uploaded 18 July 2012]   |  

Abstract

Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports. View Full-Text
Keywords: cancer immunotherapy; monoclonal antibodies; antibody engineering; bispecific antibodies cancer immunotherapy; monoclonal antibodies; antibody engineering; bispecific antibodies
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Stamova, S.; Koristka, S.; Keil, J.; Arndt, C.; Feldmann, A.; Michalk, I.; Bartsch, H.; Bippes, C.C.; Schmitz, M.; Cartellieri, M.; Bachmann, M. Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies 2012, 1, 172-198.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top